Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a critical regulator of cholesterol metabolism through its interaction with the hepatic LDL receptor (LDLR). PCSK9 is an endopeptidase that binds to the EGFR-like domain of LDLR, leading to LDLR degradation, which in turn, results in increased circulating LDL. Inhibiting the PCSK9-LDLR interaction is an increasingly desirable therapeutic approach for lowering LDL-cholesterol levels to replace or supplement statins. New therapies are critical for addressing atherosclerosis, stroke, heart disease, and other cardiovascular disorders.

We offer rapid and dependable screening and profiling services for PCSK9:LDLR inhibitors. Our team of experts, using our in-house developed biochemical assay kits, can provide:

• Screening for active compounds (small molecules, peptides, or antibodies)

• Determination of IC₅₀

• Project guidance and questions answered in a timely manner

• Delivery of detailed results promptly and on time

Available Service Assays

如果您需要了解更多关于我们的服务的信息，请联系info。